Shahnawaz Jamali, Ghulam Rasool Mashori, Zareena Maher, Moosa Khan.
Comparison of Candesartan cilexetil and atenolol in essential hypertensive patients.
Med Channel Jan ;14(1):28-31.

OBJECTIVE: To compare "Blood pressure lowering effects of candesartan cilexetil and Atenolol in essential hypertensive patients." BACKGROUND: Angiotensin II type 1 receptor antagonist are relatively a new class of anti hypertensive agents. Candesartan cilexetil has been reported to lower blood pressure as effectively as ACE inhibitors. We conducted randomized open – label, prospective comparative study to assess the efficacy of candesartan cilexetil 16 mg in newly diagnosed essential hypertension versus Atenolol 50 mg. METHODS AND MATERIALS: Patients newly diagnosed with essential hypertension were enrolled (80) and divided into two groups received candesartan 16 mg (DRI) and Atenolol 50 mg (DR2) for 3 months. At the end of study period the parameters examined were systolic blood pressure and diastolic blood pressure. RESULTS: The results have been expressed as mean ±SEM. The mean systolic blood pressure was decreased significantly for DRI group (from 162.5 ±2.01mmHg to 134.21 ±0.51 mmHg; p<0.001) versus DR2 (from 159.62 ± 2.08mmHg to 137.08 4±0.92mmHg; p<0.001). A reduction of 17% in DRI and 14% in DR2 was observed. The mean diastolic pressure was decreased significantly for DRI group (from 97.75 ±0.71mmHg to 81.44 ±0.49mmHg; p<0.001) versus DR2 (from 99.37 ±0.80mmHg to 87.63 ±0.73mHg; p<0.001). A reduction 16.25% and 12% was observed in mean diastolic blood pressure respectively. CONCLUSION: candesartan cilexetil is a newer option for decreasing blood pressure and has been reported with less side effects in comparison to Atenolol in newly diagnose essential hypertensive patients.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com